1. France Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Spineway SA

Spineway SA

0.09
EUR
+0.00
(+0.43%)
5.21MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
78,477.39
58,392.31
64,541.91
52,767.71
81,866.78
8,228.4
1,016,385.8
11,984.45
21,887.76
0.65
1,319.49
0.08
0.36
- -
Basic EPS, GAAP
-612.05
-18,939.98
-19,153.84
-23,344.92
-3,917.8
-6,625.66
-666,387.6
-48,193.74
-8,081.63
-0.27
-816.61
-0.03
-0.06
- -
Free Cash Flow per Basic Share
-22,511.9
-29,397.73
-8,625
-14,402.06
747.66
-2,261.36
-58,800
-709.22
-9,158.16
-0.14
-730.93
-0.02
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
1,286,209.6
36,166.51
106,530.61
12,086.22
266.44
0.84
0.65
0.65
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
1,202,553.6
31,651.08
96,102.04
6,977.48
136.88
0.51
0.38
0.38
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
11
- -
146
35
35
Sales/Revenue/Turnover
7
5
6
5
9
7
5
3
4
7
11
12
12
- -
Operating Margin (%)
-4.32
-39.53
-37.37
-46.26
-9.02
-40.56
-33.83
-51.88
-32.87
-42.86
-40.56
-7.4
-12.94
- -
Depreciation Expense
- -
1
1
1
1
2
2
1
- -
- -
1
1
1
- -
Net Income, GAAP
- -
-2
-2
-2
- -
-5
-3
-14
-2
-3
-7
-4
-2
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-0.78
-32.44
-29.68
-44.24
-4.79
-80.52
-65.56
-402.14
-36.92
-42.21
-61.89
-32.34
-18
- -
Working Capital
6
8
6
5
6
4
3
7
17
10
5
10
8
8
LT Debt
2
5
4
4
4
4
2
3
2
3
2
2
2
2
Total Equity
5
5
3
2
3
1
6
10
21
22
19
24
23
23
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-1.61
-34.2
-44.1
-87.28
-15.07
-217.24
-84.72
-163.45
-10.19
-14.63
-31.71
-17.85
-9.46
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
- -
2
- -
LT Borrowings
2
- -
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
29
36
36
Market Capitalization
2
4
5

Working Capital

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
14
13
13
Cash, Cash Equivalents & STI
5
4
3
Accounts Receivable, Net
3
3
3
Inventories
5
5
5
Total Current Liabilities
4
6
4
Payables & Accruals
- -
- -
- -
ST Debt
- -
2
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
49.65%
23.81%
-4.88%
Free Cash Flow
-156.74%
181.72%
-95.02%
Net Income, GAAP
141.05%
6.9%
-42.1%
Sales/Revenue/Turnover
13.95%
31.87%
4.02%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
11
2024
- -
- -
12
2025
- -
- -
12

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-816.61
2024
- -
- -
-0.03
2025
- -
- -
-0.06

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Stéphane Le Roux
Full Time Employees
43
Sector
Health technology
Industry
Medical specialties
Address
7, allEe Moulin Berger Écully AR France 69130
IPO Date
Feb 13, 2013
Website
spineway.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Spineway S.A. (ALSPW.PA) develops, manufactures, and distributes medical implants and surgical instruments for spinal surgery. The company offers a comprehensive portfolio of products including the Jackson lordosis stops system for degenerative pathologies; the Crystal cage range for interbody fusion; the Oria cervical disc prosthesis; the Barricaid device for annular closure; the iBalance dynamic stabilization bar; and the OptiMesh and OptiFix mesh systems for facet joint augmentation, along with related surgical instrumentation. These solutions target hospitals, clinics, and orthopedic surgeons treating conditions such as degenerative disc disease, spinal stenosis, and trauma in the spinal implant segment of the orthopedic medical device industry. Founded in 2005 and headquartered in Lyon, France, Spineway operates primarily in Europe, with distribution networks extending to North Africa, the Middle East, and Latin America through subsidiaries and partnerships. The company serves healthcare providers focused on minimally invasive and innovative spinal treatments, emphasizing affordable, high-quality alternatives to major competitors. No significant recent partnerships, funding rounds, acquisitions, product launches, or strategic shifts have been publicly reported in the last 1-2 years.